TABLE 4.
Implementation of Hib vaccine in countries of the WHO African Regiona
| Country | Yr of Introduction | NIP | Formulation in 2019 | Schedule in 2019 | Coverage of Hib3 in 2019 (%) | Yr in which coverage reached ≥50% |
|---|---|---|---|---|---|---|
| Algeria | 2008 | Yes | DTaP/HepB/Hib/IPV | 2, 4, 12 mo | 91 | 2008 |
| Angola | 2006 | Yes | DTwP/HepB/Hib | 2, 4, 6 mo | 53 | 2010 |
| Benin | 2005 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 76 | 2006 |
| Botswana | 2011 | Yes | DTwP/HepB/Hib | 2, 3, 4 mo | 95 | 2011 |
| Burkina Faso | 2006 | Yes | DTwP/HepB/Hib | 8, 12, 16 wks | 91 | 2006 |
| Burundi | 2004 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 93 | 2004 |
| Cameroon | 2009 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 67 | 2009 |
| Cabo Verde | 2010 | Yes | DTwP/HepB/Hib | 2, 4, 6, 18 mo | 97 | 2011 |
| The Central African Republic | 2008 | Yes | DTwP/HepB/Hib | 6, 10 14 wks | 47 | |
| Chad | 2008 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 50 | |
| Comoros | 2009 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 91 | 2009 |
| The Congo | 2009 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 79 | 2009 |
| Côte d’Ivoire | 2009 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 84 | 2009 |
| The Democratic Republic of the Congo | 2008 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 57 | 2009 |
| Equatorial Guinea | 2013 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 53 | 2016 |
| Eritrea | 2008 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 95 | 2008 |
| Ethiopia | 2007 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 68 | 2008 |
| Gabon | 2010 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 70 | 2010 |
| The Gambia | 1997 | Yes | DTwP/HepB/Hib | 2, 3, 4 mo | 88 | 1998 |
| Ghana | 2002 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 97 | 2002 |
| Guinea | 2008 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 45 | 2009 (<50% in 2014) |
| Guinea-Bissau | 2008 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 84 | 2009 |
| Kenya | 2001 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 92 | 2002 |
| Lesotho | 2008 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 87 | 2009 |
| Liberia | 2008 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 74 | 2008 |
| Madagascar | 2008 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 79 | 2008 |
| Malawi | 2002 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 95 | 2002 |
| Mali | 2007 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 77 | 2008 |
| Mauritania | 2009 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 81 | 2009 |
| Mauritius | 2006 | Yes | DTaP/HepB/Hib/IPV | 6, 10, 14 wks, 18 mo | 97 | 2006 |
| Mozambique | 2009 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 88 | 2009 |
| Namibia | 2009 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 87 | 2010 |
| Niger | 2008 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 81 | 2009 |
| Nigeria | 2012 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 57 | 2016 |
| Rwanda | 2002 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 98 | 2002 |
| Sao Tome and Principe | 2009 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 95 | 2010 |
| Senegal | 2005 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 93 | 2006 |
| Seychelles | 2010 | Yes | DTwP/HepB/Hib | 3, 4, 5 mo | 99 | 2010 |
| Sierra Leone | 2007 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 95 | 2007 |
| South Africa | 1999 | Yes | DTaP/HepB/Hib/IPV | 6, 10, 14 wks, 18 mo | 77 | 2000 |
| South Sudan | 2014 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 49 | |
| Eswatini (Swaziland) | 2009 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 90 | 2009 |
| Togo | 2008 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 84 | 2009 |
| Uganda | 2002 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 93 | 2004 |
| The United Republic of Tanzania | 2009 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 89 | 2009 |
| Zambia | 2004 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 88 | 2004 |
| Zimbabwe | 2008 | Yes | DTwP/HepB/Hib | 6, 10, 14 wks | 90 | 2008 |
a
Annual birth cohort, 35.7 million. Children aged <5 years, 170.2 million. Seventy-three percent of target population was immunized with three doses of Hib (Hib3) in 2019 (based on WHO-UNICEF estimates) (136). NIP, national immunization program. Abbreviations of vaccine antigens: D, diphtheria; T, tetanus; aP, acellular pertussis; wP, whole-cell pertussis; Hib, Haemophilus influenzae type b; HepB, hepatitis B virus surface antigen; IPV, inactivated poliovirus.